Retatrutide

产品详情：

更新时间： 2026-05-27 00:21:29

CAS号：2381089-83-2

常用名： LY3437943

价格：
$432.12/10mg $6847.04/1g

纯度： 98.77%

备货期： 3天

库存： 现货

产品页： http://www.zhaokebio.com

其他详情（用途，包装）：
Retatrutide (development code LY3437943) is a first-in-class triple hormone receptor agonist peptide developed by Eli Lilly and Company, designed for the treatment of obesity and type 2 diabetes. It simultaneously activates three distinct metabolic hormone receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG), delivering unprecedented synergistic effects on body weight reduction, glycemic control, and metabolic health.
Retatrutide is a 39-amino-acid linear peptide engineered from the native oxyntomodulin sequence with strategic amino acid substitutions to optimize receptor binding profiles. The peptide is conjugated to a C20 fatty diacid moiety via a gamma-Glu-AEEA-Lys linker at Lys20, enabling strong albumin binding and an extended half-life of approximately 6 days, which supports once-weekly subcutaneous administration. Clinical trials have demonstrated record-breaking efficacy: Phase 2 trials showed up to 24.2% mean weight reduction at 48 weeks, while Phase 3 TRIUMPH-4 trial demonstrated 28.7% weight loss (71.2 lbs) at 68 weeks in participants with obesity and knee osteoarthritis.
Shenzhen Zhaoke Biotechnology Co., Ltd. provides high-purity Retatrutide API (CAS No.: 2381089-83-2) with comprehensive analytical documentation for global pharmaceutical developers and research institutions.
Key Selling Points: Triple Receptor Agonism-Simultaneously activates GIP, GLP-1, and glucagon receptors, delivering synergistic metabolic benefits that surpass single- or dual-agonist therapies. The unique triple mechanism enables superior weight loss and glycemic control.
Breakthrough Weight Loss Efficacy-Phase 2: 24.2% weight loss at 48 weeks; Phase 3 TRIUMPH-4: 28.7% (71.2 lbs) at 68 weeks. Over 90% of participants achieved ≥10% weight loss at 12 mg dose. The weight loss curve had not plateaued at trial end.
Osteoarthritis Pain Relief-Phase 3 TRIUMPH-4 demonstrated 75.8% reduction in WOMAC pain scores. Over 12% of treated participants became completely free of knee pain, significantly outperforming semaglutide (42% pain reduction).
Once-Weekly Dosing-C20 fatty diacid conjugation enables albumin binding with a ~6-day half-life, supporting convenient once-weekly subcutaneous injection for improved patient adherence.
Superior Metabolic Profile-Reduces A1C by up to 2.0%, lowers non-HDL cholesterol and triglycerides, and decreases systolic blood pressure. Total fat mass reduced by 26.1% with comparable lean mass preservation.
Well-Tolerated Safety-Side effect profile consistent with GLP-1/GIP receptor agonists. Gastrointestinal events (nausea, diarrhea, vomiting) are the most common and typically transient. No new safety signals identified.

供应商信息：

公司名：深圳兆科生物技术有限公司

认证状态： 未认证供应商

商品数： 18件

电话： 0086-19842673490

地址： 坪山区坑梓街道金沙社区锦绣东路22号雷柏中城生命科学园第3分园A栋 208

地区： 深圳市龙岗区

联系人： 张玉君

联系人电话： 19842673490

邮件：jade.cheung@zhaokebio.com

网址：http://www.zhaokebio.com

主要市场：North America, Western Europe, Midde East, South Asia

年贸易额：10,000,000

外贸占销售比例：100%

主要合作伙伴：

公司介绍：
深圳兆科生物科技有限公司作为一家专业的全球采购与供应链解决方案供应商，专注于提供高品质的肽类原料药服务。我们并非从事制造业务，而是将核心能力集中于从全球医药领域内的合格供应商处进行战略性采购、严格审核以及可靠地交付优质肽类产品。
我们扮演着连接世界级肽类生产商与北美、欧洲、亚太地区及新兴市场的制药研发企业、研究机构及制造企业之间的关键纽带。我们的使命在于消除采购过程中的复杂性，降低供应风险，并确保在整个采购流程的每个阶段都能保持无可妥协的品质。

其他供应商价格：

2025-02-05 价格：￥7999.9 Retatrutide 钠盐

2024-09-20 价格：￥1.0 雷塔鲁肽

2024-07-15 价格：需询单 Retatrutide

2024-09-14 价格：￥需询单 Retatrutide weight-loss peptide

2023-08-03 价格：￥需询单 GIPR/GLP-1R/GCGR激动剂多肽;LY3437943

2023-11-15 价格：￥需询单 Retatrutide

2023-10-27 价格：￥13500.0 Retatrutide

2024-12-10 价格：￥需询单 Retatrutide 99% White powder High Quality Retatrutide weight loss GIPR/GLP-1R/GCRG Peptide

2025-04-16 价格：￥需询单瑞他鲁肽 Retatrutide

查看所有价格请点击：

LY3437943价格

Retatrutide

产品详情：

供应商信息：

推荐生产厂家/供应商：

其他供应商价格：

相关产品价格：